|
|||||
|
|
Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind,randomized, placebo-controlled study-(PURSUIT-J study) |
|
| Authors: | Hibi Toshifumi Imai Yuya Senoo Asako Ohta Kentaro Ukyo Yoshifumi |
| Affiliation: | 1.Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8462, Japan ;2.Janssen Pharmaceutical K.K., Tokyo, Japan ; |
| Abstract: | Journal of Gastroenterology - The global phase 3 studies of golimumab [PURSUIT-SC and PURSUIT-maintenance (M)], an anti-tumor necrosis factor-α (anti-TNFα) antibody, have demonstrated... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |